Diabetes Drugs Repurposed to Lower Dementia Risk
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Diabetes raises the risk of developing dementia by about 60%, and frequent episodes of low blood sugar are linked to a 50% higher chance of cognitive decline.
- APOE4, the highest genetic risk factor for Alzheimer's, reduces insulin sensitivity by trapping insulin receptors inside cells where they cannot be activated, according to the article.
- Memantine, a drug now used to treat moderate to severe Alzheimer's symptoms, was originally developed as a diabetes medication that failed to control blood glucose but was later found to benefit brain function.
- Metformin, the most widely used diabetes drug, may lower brain inflammation, and people with diabetes who take it appear less likely to develop dementia — with risk rising again if they stop; trials are now testing it in non-diabetic patients.
- GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) are associated with lower dementia risk in diabetic patients and may outperform metformin, while the Evoke and Evoke Plus trials are testing oral semaglutide in people with mild cognitive impairment or early Alzheimer's.
- SGLT2 inhibitors may be even more effective than GLP-1 drugs at reducing dementia risk — including Alzheimer's and vascular dementia — in type 2 diabetes patients, possibly by reducing inflammation in the brain.
- Intranasal insulin sprays designed to deliver insulin directly to the brain have shown early signs of improving memory and reducing brain shrinkage in small studies, though the article notes long-term safety remains unproven.
Why it matters: Roughly 60% increased dementia risk for people with diabetes gives the hundreds of millions living with type 2 diabetes a direct stake in emerging research showing that their existing medications — metformin, Ozempic, and SGLT2 inhibitors — may simultaneously protect brain function, potentially reshaping how clinicians prescribe these drugs as the Evoke and Evoke Plus trials report results.
